357.27
price up icon3.45%   11.90
pre-market  プレマーケット:  359.98   2.71   +0.76%
loading
前日終値:
$345.37
開ける:
$347.59
24時間の取引高:
1.18M
Relative Volume:
0.94
時価総額:
$17.06B
収益:
$4.03B
当期純損益:
$-182.84M
株価収益率:
-95.01
EPS:
-3.7603
ネットキャッシュフロー:
$391.29M
1週間 パフォーマンス:
+13.26%
1か月 パフォーマンス:
+22.00%
6か月 パフォーマンス:
+108.65%
1年 パフォーマンス:
+82.95%
1日の値動き範囲:
Value
$0.00
$0.00
1週間の範囲:
Value
$313.83
$357.77
52週間の値動き範囲:
Value
$146.19
$357.77

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
名前
Charles River Laboratories International Inc
Name
セクター
Healthcare (1053)
Name
電話
781-222-6000
Name
住所
251 BALLARDVALE ST, WILMINGTON, MA
Name
職員
19,700
Name
Twitter
@criverlabs
Name
次回の収益日
2026-11-04
Name
最新のSEC提出書
Name
CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, NTRA, A, IQV

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CRL icon
CRL
Charles River Laboratories International Inc
357.27 17.06B 4.03B -182.84M 391.29M -3.7603
TMO icon
TMO
Thermo Fisher Scientific Inc
684.89 253.24B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
232.97 163.77B 24.78B 3.68B 5.29B 5.1743
NTRA icon
NTRA
Natera Inc
404.90 58.36B 2.50B -226.32M 71.51M -1.6412
A icon
A
Agilent Technologies Inc
175.96 49.61B 7.23B 1.41B 1.09B 4.979
IQV icon
IQV
Iqvia Holdings Inc
273.60 45.03B 16.63B 1.39B 2.12B 8.0674

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-30 再開されました UBS Buy
2026-08-06 アップグレード JP Morgan Neutral → Overweight
2026-07-20 ダウングレード CLSA Outperform → Hold
2026-06-17 アップグレード Morgan Stanley Equal-Weight → Overweight
2026-05-29 アップグレード CLSA Hold → Outperform
2026-04-14 開始されました RBC Capital Mkts Outperform
2025-12-15 アップグレード BofA Securities Neutral → Buy
2025-11-17 アップグレード Argus Hold → Buy
2025-11-06 アップグレード Robert W. Baird Neutral → Outperform
2025-10-06 アップグレード William Blair Mkt Perform → Outperform
2025-10-02 アップグレード Barclays Equal Weight → Overweight
2025-09-09 アップグレード Jefferies Hold → Buy
2025-07-09 アップグレード Citigroup Neutral → Buy
2025-05-23 アップグレード Redburn Atlantic Neutral → Buy
2025-05-14 アップグレード TD Cowen Hold → Buy
2025-05-08 アップグレード Evercore ISI In-line → Outperform
2025-03-21 ダウングレード Goldman Buy → Neutral
2025-03-04 アップグレード Citigroup Sell → Neutral
2025-03-03 アップグレード Redburn Atlantic Sell → Neutral
2025-01-22 ダウングレード William Blair Outperform → Mkt Perform
2025-01-17 ダウングレード UBS Buy → Neutral
2024-11-18 ダウングレード CLSA Hold → Underperform
2024-11-07 アップグレード CLSA Underperform → Hold
2024-10-23 開始されました CLSA Underperform
2024-10-14 開始されました Redburn Atlantic Sell
2024-10-07 ダウングレード Evercore ISI Outperform → In-line
2024-10-02 ダウングレード BofA Securities Buy → Neutral
2024-10-01 ダウングレード Citigroup Neutral → Sell
2024-08-08 ダウングレード JP Morgan Overweight → Neutral
2024-08-08 ダウングレード Robert W. Baird Outperform → Neutral
2024-06-28 ダウングレード Argus Buy → Hold
2024-06-07 開始されました Mizuho Neutral
2024-06-06 開始されました Goldman Buy
2024-02-15 ダウングレード Guggenheim Buy → Neutral
2023-09-13 開始されました TD Cowen Market Perform
2023-07-10 ダウングレード Citigroup Buy → Neutral
2023-02-23 アップグレード Guggenheim Neutral → Buy
2023-01-12 ダウングレード Jefferies Buy → Hold
2022-09-30 アップグレード Jefferies Hold → Buy
2022-08-25 開始されました Credit Suisse Outperform
2022-08-04 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-05-24 開始されました Guggenheim Neutral
2022-04-25 ダウングレード Jefferies Buy → Hold
2022-04-07 開始されました Stephens Overweight
2022-02-17 繰り返されました BofA Securities Buy
2022-02-17 アップグレード Citigroup Neutral → Buy
2022-02-17 繰り返されました Deutsche Bank Buy
2022-02-17 繰り返されました Morgan Stanley Overweight
2022-02-17 繰り返されました UBS Buy
2021-08-05 再開されました Credit Suisse Neutral
2020-12-16 ダウングレード Citigroup Buy → Neutral
2020-09-10 アップグレード Jefferies Hold → Buy
2020-07-01 アップグレード BofA Securities Neutral → Buy
2020-05-13 アップグレード UBS Neutral → Buy
2020-04-21 ダウングレード Jefferies Buy → Hold
2020-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-02 開始されました Deutsche Bank Buy
2020-02-18 アップグレード Wolfe Research Peer Perform → Outperform
2020-01-10 アップグレード Goldman Neutral → Buy
2020-01-08 開始されました Wells Fargo Overweight
2020-01-07 開始されました Citigroup Buy
2019-10-18 ダウングレード BofA/Merrill Buy → Neutral
2019-06-10 開始されました SVB Leerink Outperform
2019-04-30 再開されました Evercore ISI Outperform
2018-12-14 開始されました Deutsche Bank Buy
2018-10-09 開始されました UBS Neutral
2018-08-23 アップグレード Raymond James Mkt Perform → Outperform
2018-07-17 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-06-15 アップグレード KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 アップグレード SunTrust Hold → Buy
すべてを表示

Charles River Laboratories International Inc (CRL) 最新ニュース

pulisher
Oct 26, 2026

Charles River Laboratories’ Q3 2026 Earnings: What to Expect - Yahoo Finance

Oct 26, 2026
pulisher
Oct 25, 2026

Charles River Laboratories International (CRL) Has Fresh Attention, But What Is Behind It? - Simply Wall Street

Oct 25, 2026
pulisher
Oct 23, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 23, 2026
pulisher
Oct 23, 2026

Charles River Laboratories International, Inc. Estimates – NYSE:CRL - TradingView

Oct 23, 2026
pulisher
Oct 22, 2026

Charles River Laboratories (CRL) Partners with FDA and Labcorp t - GuruFocus

Oct 22, 2026
pulisher
Oct 22, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 22, 2026
pulisher
Oct 22, 2026

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Finviz

Oct 22, 2026
pulisher
Oct 22, 2026

Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5 - Yahoo Finance

Oct 22, 2026
pulisher
Oct 21, 2026

$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today - Benzinga

Oct 21, 2026
pulisher
Oct 21, 2026

Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype - Timothy Sykes

Oct 21, 2026
pulisher
Oct 21, 2026

Charles River Laboratories International Jumps 7.3% in Broad Rally - AlphaStreet

Oct 21, 2026
pulisher
Oct 21, 2026

Charles River Labs Stock Jumps As Street Hikes Targets - StocksToTrade

Oct 21, 2026
pulisher
Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD - Investing.com

Oct 21, 2026
pulisher
Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD By Investing.com - Investing.com South Africa

Oct 21, 2026
pulisher
Oct 20, 2026

Is Charles River Laboratories International Inc (CRL) Overvalued After 5.1% Rally? GF Value Says Overvalued - GuruFocus

Oct 20, 2026
pulisher
Oct 20, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 20, 2026
pulisher
Oct 20, 2026

Dilution adjustment of Charles River Laboratories International, Inc. – XETR:RV6 - TradingView

Oct 20, 2026
pulisher
Oct 20, 2026

Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00 - ad-hoc-news.de

Oct 20, 2026
pulisher
Oct 20, 2026

AI-Driven Drug Discovery Boosts Charles River Laboratories (CRL) Prospects - GuruFocus

Oct 20, 2026
pulisher
Oct 20, 2026

Citrini Bets on Life Sciences Stocks After Claude AI Drug Study - Bloomberg.com

Oct 20, 2026
pulisher
Oct 17, 2026

Charles River Laboratories International (CRL) Earnings Beat Puts Fair Value Back In Focus - Simply Wall Street

Oct 17, 2026
pulisher
Oct 17, 2026

Charles River Laboratories International, Inc. (CRL) Options ChainYahoo Finance - Yahoo! Finance Canada

Oct 17, 2026
pulisher
Oct 16, 2026

Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 16, 2026
pulisher
Oct 16, 2026

ETFs Are Net Sellers of Charles River (CRL) on Wednesday - Yahoo Finance

Oct 16, 2026
pulisher
Oct 16, 2026

Apollo Orchestrate digitizes lab workflows - Select Science

Oct 16, 2026
pulisher
Oct 15, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Oct 15, 2026
pulisher
Oct 15, 2026

CRLFuture Testing Mix Shift And Create The Future Program Will Support Stable Outlook - Simply Wall Street

Oct 15, 2026
pulisher
Oct 14, 2026

Is Stem Cell Testing Deal Altering The Investment Case For Charles River Stock? - Simply Wall Street

Oct 14, 2026
pulisher
Oct 14, 2026

JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310 - Yahoo Finance

Oct 14, 2026
pulisher
Oct 14, 2026

Charles River partners with Magellan Stem Cells on cell therapy - Yahoo Finance

Oct 14, 2026
pulisher
Oct 13, 2026

Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy - Yahoo Finance

Oct 13, 2026
pulisher
Oct 12, 2026

Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $324.87, Implies 8% Upside - TradingView

Oct 12, 2026
pulisher
Oct 12, 2026

Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera - GlobeNewswire Inc.

Oct 12, 2026
pulisher
Oct 12, 2026

Form 144 CHARLES RIVER LABORATORIES INTERNATIONAL For: 12 October By Investing.com - Investing.com Canada

Oct 12, 2026
pulisher
Oct 10, 2026

Is Charles River Laboratories International (CRL) Fairly Valued After The Apollo Orchestrate Launch? - Simply Wall Street

Oct 10, 2026
pulisher
Oct 09, 2026

Q2 2026 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus

Oct 09, 2026
pulisher
Oct 09, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 09, 2026
pulisher
Oct 09, 2026

Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - BioSpace

Oct 09, 2026
pulisher
Oct 09, 2026

Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - Business Wire

Oct 09, 2026
pulisher
Oct 08, 2026

Charles River and Autolomous launch Apollo Orchestrate for digital laboratory execution - BioSpectrum Asia

Oct 08, 2026
pulisher
Oct 07, 2026

Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com Nigeria

Oct 07, 2026
pulisher
Oct 07, 2026

Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com

Oct 07, 2026
pulisher
Oct 07, 2026

Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com India

Oct 07, 2026
pulisher
Oct 07, 2026

Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com UK

Oct 07, 2026
pulisher
Oct 07, 2026

Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 07, 2026
pulisher
Oct 07, 2026

PGNY or CRL: Which Is the Better Value Stock Right Now? - Zacks Investment Research

Oct 07, 2026
pulisher
Oct 07, 2026

Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research

Oct 07, 2026
pulisher
Oct 07, 2026

Charles River Gains 75.8% in a Year: What's Driving the Rally? - Yahoo! Finance Canada

Oct 07, 2026
pulisher
Oct 07, 2026

Charles River Gains 75.8% in a Year: What's Driving the Rally? - TradingView

Oct 07, 2026
pulisher
Oct 07, 2026

Could Apollo Orchestrate Launch Shift Charles River Labs Stock Narrative - Simply Wall Street

Oct 07, 2026

Charles River Laboratories International Inc (CRL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Charles River Laboratories International Inc (CRL) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
FOSTER JAMES C
Director
Oct 22 '26
Proposed Sale
350.00
24,042
8,414,700
0
FOSTER JAMES C
Director
Oct 22 '26
Sale
350.00
24,042
8,414,700
31,596
Parisotto Shannon M
CEVP, Disc & Safety Assessment
Oct 21 '26
Sale
344.41
2,156
742,548
4,807
Parisotto Shannon M
Officer
Oct 21 '26
Proposed Sale
344.41
2,156
742,548
0
Parisotto Shannon M
CEVP, Disc & Safety Assessment
Oct 21 '26
Option Exercise
244.41
2,156
526,948
6,963
Parisotto Shannon M
CEVP, Disc & Safety Assessment
Oct 05 '26
Option Exercise
208.44
981
204,480
5,788
Parisotto Shannon M
CEVP, Disc & Safety Assessment
Oct 05 '26
Sale
308.44
981
302,580
4,807
Parisotto Shannon M
Officer
Oct 05 '26
Proposed Sale
314.56
981
308,580
0
Coleman Glenn
EVP & Chief Financial Officer
Sep 30 '26
Buy
297.43
10
2,974
27,762
FOSTER JAMES C
Director
Aug 25 '26
Option Exercise
199.42
33,561
6,692,845
65,157
$160.39
price up icon 1.02%
$676.77
price up icon 1.13%
$183.78
price down icon 0.80%
GH GH
$173.25
price up icon 2.47%
$50.37
price down icon 0.04%
LH LH
$329.90
price up icon 0.29%
大文字化:     |  ボリューム (24 時間):